Biological Basis and Proposed Mechanism of Action of CSL112 (Apolipoprotein A-I [Human]) for Prevention of Major Adverse Cardiovascular Events in Patients post Myocardial Infarction

被引：0
|
作者：
Kazmi, Syed Hassan A. [1 ]
Korjian, Serge [1 ]
Chi, Gerald [1 ]
Kalayci, Arzu [1 ]
Lee, Jane J. [1 ]
Talib, Usama [1 ]
Wright, Samuel D. [1 ]
Duffy, Danielle [1 ]
Kingwell, Bronwyn A. [1 ]
Mehran, Roxana [1 ]
Ridker, Paul M. [1 ]
机构：
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA
来源：
AMERICAN HEART JOURNAL | 2021年 / 242卷
关键词：
D O I：
10.1016/j.ahj.2021.10.033
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0043
引用
收藏
页码：158 / 158
页数：1
相关论文
共 20 条
  • [1] Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
    Korjian, Serge
    Kazmi, Syed Hassan A.
    Chi, Gerald
    Kalayci, Arzu
    Lee, Jane J.
    Talib, Usama
    Wright, Samuel D.
    Duffy, Danielle
    Kingwell, Bronwyn A.
    Mehran, Roxana
    Ridker, Paul M.
    Gibson, C. Michael
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2023, 9 (04) : 387 - 398
  • [2] CSL112 (Apolipoprotein A-I (Human)) Infusion in Post Myocardial Infarction Patients Promotes Hepatocyte Cholesterol Uptake Ex Vivo
    Velkoska, Elena
    Greene, Brandon
    Collins, Heidi L.
    Adelman, Steven
    Mears, Jenny
    Duffy, Danielle
    Gibson, C. Michael
    Diditchenko, Svetlana
    Kingwell, Bronwyn A.
    CIRCULATION, 2022, 146
  • [3] CSL112 (human apolipoprotein A-I) infusion rapidly increases apoA-I exchange rate (AER) when administered to patients post myocardial infarction
    Kingwell, B. A.
    Velkoska, E.
    Diditchenko, S.
    Greene, B. H.
    Wang, S.
    Mears, J.
    Wright, S. D.
    Gibson, C. M.
    Smith, J. D.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1212 - 1212
  • [4] CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial Infarction
    Kingwell, Bronwyn A.
    Duffy, Danielle
    Clementi, Regina
    Velkoska, Elena
    Feaster, John
    Gibson, C. Michael
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (09):
  • [5] Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients
    Zheng, Bo
    Duffy, Danielle
    Tricoci, Pierluigi
    Kastrissios, Helen
    Pfister, Marc
    Wright, Samuel D.
    Gille, Andreas
    Tortorici, Michael A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (06) : 2558 - 2571
  • [6] CSL112 (apolipoprotein A-I [human]) reduces the elevation in neutrophil-lymphocyte ratio (NLR) induced by acute myocardial infarction
    Kingwell, B.
    Duffy, D.
    Clementi, R.
    Velkoska, E.
    Feaster, J.
    Gibson, C. M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [7] CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction
    Capodanno, Davide
    Mehran, Roxana
    Gibson, C. Michael
    Angiolillo, Dominick J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (12) : 997 - 1005
  • [8] The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
    Gibson, C. Michael
    Kerneis, Mathieu
    Yee, Megan K.
    Daaboul, Yazan
    Korjian, Serge
    Mehr, Ali Poyan
    Tricoci, Pierluigi
    Alexander, John H.
    Kastelein, John J. P.
    Mehran, Roxana
    Bode, Christoph
    Lewis, Basil S.
    Mehta, Ravindra
    Duffy, Danielle
    Feaster, John
    Halabi, Majdi
    Angiolillo, Dominick J.
    Duerschmied, Daniel
    Ophuis, Ton Oude
    Merkely, Bela
    AMERICAN HEART JOURNAL, 2019, 208 : 81 - 90
  • [9] In perspective: CSL112 (apolipoprotein A-I) infusions and cardiovascular outcomes in patients with acute myocardial infarction: the ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II) trial
    Verbrugge, Frederik H.
    Krychtiuk, Konstantin A.
    EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2024, 13 (04) : 362 - 364
  • [10] CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
    Gille, Andreas
    D'Andrea, Denise
    Tortorici, Michael A.
    Hartel, Gunter
    Wright, Samuel D.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (04) : 953 - 963
12